The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: Convergence with the anti-apoptotic effect of thyroid hormone

Cell Cycle

Volumn 8, Issue 12, 2009, Pages 1877-1882

  Lin, Hung Yun ^a   Davis, Paul J ^a,b   Tang, Heng Yuan ^a   Mousa, Shaker A ^c   Luidens, Mary K ^a,b   Hercbergs, Aleck H ^d   Davis, Faith B ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Cyclooxygenase 2; Mitogen activated protein kinase; Resveratrol

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; RESVERATROL; STILBENE; STILBENE DERIVATIVE; THYROID HORMONE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; HYPOTHYROIDISM; NONHUMAN; REVIEW;

EID: 67649333081     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.12.8747     Document Type: Review

References (102)

1. Smith WL. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trend Biochem Sci 2008; 33:27-37.
2. Lanas A, Ferrandez A. NSAIDs and the colon. Curr Opin Gastroenterol 2009; 25:44-49
3. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 2007; 38:78-82.
4. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001; 98:2598-2603 (Pubitemid 32209528)
5. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95:681-686 (Pubitemid 28083803)
6. Shih A, Davis FB, Lin HY, Davis PJ. Resveratrol induces apoptosis that is MAPK- and p53-dependent in thyroid cancer cell lines. J Clin Endocrinol Metab 2002; 87:1223-1232 (Pubitemid 36121092)
7. Lin HY, Shih A, Davis FB, Tang HY, Bennett J, Davis PJ. Resveratrol-induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002; 168:748-755 (Pubitemid 34793357)
8. Zhang SL, Cao JH, Davis FB, Tang HY, Davis PJ, Lin HY. Estrogen inhibits resveratrol-induced posttranslational modification of p53 and apoptosis in breast cancer cells. Brit J Cancer 2004; 91:178-185 (Pubitemid 39013062)
9. Shih A, Zhang SL, Cao JH, Boswell S, Wu Y-S, Tang HY, et al. Inhibitory effect of EGF on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-α. Mol Cancer Ther 2004; 3:1355-1364
10. Lin HY, Lansing L, Merillon J-M, Davis FB, Tang H-Y, Shih A, et al. Integrin alpha(V) beta3 contains a receptor site for resveratrol. FASEB J 2006; 20:1742-1744
11. Tang HY, Shih A, Cao JH, Davis FB, Davis PJ, Lin HY. Inducible COX-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006; 5:2034-2204
12. Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ, et al. Thyroxine induces MAPK activation and blocks resveratrol-induced apoptosis in human thyroid cancer cell lines. Steroids 2007; 72:180-187
13. Lin HY, Tang HY, Keating T, Wu Y-H, Shih A, Hammond D, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: Both actions are integrin- and ERK-mediated. Carcinogenesis 2008; 29:62-69 (Pubitemid 351201742)
14. Lin HY, Sun MZ, Tang HY, Wu Y-H, Simone T, Grandis JR, et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008; 104:2131-2142
15. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F. Resveratrol: from basic science to the clinic. Cell Cycle 2007; 6:2495-2510 (Pubitemid 350058668)
16. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life 2008; 60:323-332
17. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7:1020-1035 (Pubitemid 351679835)
18. Ovesná Z, Horváthová-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues. Neoplasma 2005; 52:450-455 (Pubitemid 41809401)
19. Greiling D, Clark RA. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 1997; 110:861-870 (Pubitemid 27196785)
20. Scatena M, Giachelli C. The alpha(v)beta3 integrin, NFkappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 2002; 12:83-88
21. Sakamoto Y, Ogita H, Hirota T, Kawakatsu T, Fukuyama T, Yasumi M, et al. Interaction of integrin alpha(v)beta3 with nectin. Implication in cross-talk between cell-matrix and cell-cell junctions. J Biol Chem 2006; 281:19631-19644
22. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005; 102:7589-7594 (Pubitemid 40741015)
23. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of MAPK and induction of angiogenesis. Endocrinology 2005; 146:2864-2871
24. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, et al. The proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 94:1500-1506 (Pubitemid 38780323)
25. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008; 11:183-190
26. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7:429-434 (Pubitemid 32183049)
27. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res 2007; 27:3765-3770 (Pubitemid 47598442)
28. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 2007; 104:320-325 (Pubitemid 46135664)
29. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-78 (Pubitemid 30004877)
30. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8:97-114. (Pubitemid 32641352)
31. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62:632-635 (Pubitemid 34126931)
32. Narko K, Zweifel B, Trifan O, Ristimaki A, Lane TF, Hla T. COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat 2005; 76:86-94. (Pubitemid 40720405)
33. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003; 7:207-222 (Pubitemid 37372041)
34. Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ. Chemoprevention for colon cancer: new opportunities, fact or fiction? Scand J Gastroenterol Suppl 2006; 243:158-164
35. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003; 48:1998-2002. (Pubitemid 37410090)
36. Muzio G, Trombetta A, Maggiora M, Martinasso G, Vasiliou V, Lassen N, et al. Arachidonic acid suppresses growth of human lung tumor A549 cells through downregulation of ALDH3A1 expression. Free Radic Biol Med 2006; 40:1929-1938 (Pubitemid 44250821)
37. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97:11280-11285 (Pubitemid 30780886)
38. Levine L. Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB J 2003; 17:800-802
39. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, et al. COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003; 83:1385-1394 (Pubitemid 37267822)
40. Banu N, Buda A, Chell S, Elder D, Moorghen M, Paraskeva C, et al. Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 2007; 40:768-779 (Pubitemid 47416549)
41. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418-1423
42. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716 (Pubitemid 28257578)
43. Tatsuguchi A, Matsui E, Shinji Y, Gudia K, Tsukui T, Kishida T, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004; 35:488-495 (Pubitemid 38507087)
44. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127:411-417
45. Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 2006; 66:4378-4384
46. Kuhnert F, Tam BY, Sennino B, Gray JT, Yuan J, Jocson A, et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA 2008: 105:10185-10190
47. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008; 14:2210-2219 (Pubitemid 351551134)
48. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev 2006; 20:1394-1404
49. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007; 9:569-577 (Pubitemid 47121831)
50. Mori F, Piro FR, Della Rocca C, Mesiti G, Giampaoli S, Silvestre G, et al. Survivin and cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes. Histol Histopathol 2007; 22:61-77. (Pubitemid 46126650)
51. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28:299-307. (Pubitemid 46963141)
52. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma WH, et al. Angiogenic effects of prostaglandin E2 are mediated by upregulation of CXCR4 on human microvascular endothelial cells. Blood 2003; 102:1966-1977 (Pubitemid 37122368)
53. Poggi A, Catellani S, Fenoglio D, Borsellino G, Battistini L, Zocchi MR. Adhesion molecules and kinases involved in gamma-delta T cells migratory pathways: implications for viral and autoimmune diseases. Curr Med Chem 2007; 14:3166-3170
54. Peng SB, Peek V, Zhai Y, Paul DC, Lou Q, Xia X, et al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res 2005; 3:227-236 (Pubitemid 40525333)
55. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271:33157-33160 (Pubitemid 27010118)
56. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998; 273:9886-9893 (Pubitemid 28183086)
57. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275:32783-32792 (Pubitemid 30797052)
58. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003; 278:37937-37947 (Pubitemid 37175324)
59. Ivanov AI, Romanovsky AA. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci 2004; 9:1977-1993 (Pubitemid 38922897)
60. Patel R, Attur MG, Dave M, Abramson SB, Amin AR. Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages. J Immunol 1999; 162:4191-4197 (Pubitemid 29314806)
61. Parfenova H, Eidson TH, Leffler CW. Upregulation of COX-2 in cerebral microvascular endothelial cells by smooth muscle cell signals. Am J Physiol 1997; 273:277-288 (Pubitemid 27343975)
62. Parfenova H, Parfenov VN, Shlopov BV, Levine V, Falkos S, Pourcyrous M, et al. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol Cell Physiol 2001; 281:166-178 (Pubitemid 32927327)
63. Guo Q, Kulmacz RJ. Distinct influences of carboxyl terminal segment structure on function in the two isoforms of prostaglandin H synthase. Arch Biochem Biophys 2000; 384:269-279 (Pubitemid 32012801)
64. Liou JY, Deng WG, Gilroy DW, Shyue SK, Wu KK. Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J Biol Chem 2001; 276:34975-34982 (Pubitemid 37384502)
65. Kwak JO, Lee WK, Kim HW, Jung SM, Oh KJ, Jung SY, et al. Evidence for cyclooxygenase-2 association with caveolin-3 in primary cultured rat chondrocytes. J Korean Med Sci 2006; 21:100-106 (Pubitemid 43269295)
66. Murakami M, Kambe T, Shimbara S, Yamamoto S, Kuwata H, Kudo I. Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J Biol Chem 1999; 274:29927-29936
67. Pederson T. Thinking about a nuclear matrix. J Mol Biol 1998; 277:147-159 (Pubitemid 28184161)
68. Hancock R. Internal organisation of the nucleus: assembly of compartments by macromolecular crowding and the nuclear matrix model. Biol Cell 2004; 96:595-601. (Pubitemid 39562234)
69. Nickerson JA, Blencowe BJ, Penman S. The architectural organization of nuclear metabolism. Int Rev Cytol 1995; 162:67-123. (Pubitemid 26034829)
70. Parfenova H, Balabanova L, Leffler CW. Posttranslational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol 1998; 274:72-81. (Pubitemid 128735959)
71. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004; 28:179-190 (Pubitemid 37487998)
72. Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med 2007; 356:2195-2198
73. Namkoong S, Lee SJ, Kim CK, Kim YM, Chung HT, Lee H, et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005; 37:588-600. (Pubitemid 43143521)
74. Lin HY, Tang HY, Lin C, Davis PJ, Davis FB. Inducible COX-2 is required for p53-dependent apoptosis in human prostate cancer cells treated with resveratrol 2007. Abstract 5178, Proceedings of the 98th Annual Meeting of the American Association for Cancer Research.
75. Lin HY, Hopkins R, Cao HJ, Tang HY, Alexander C, Davis FB, et al. Acetylation of nuclear hormone receptor superfamily members: thyroid hormone causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent mechanism. Steroids 2005; 70:444-449 (Pubitemid 40626763)
76. Lin HY, Zhang S, West BL, Tang HY, Passaretti T, Davis FB, et al. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-β1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 2003; 42:7571-7579 (Pubitemid 36735834)
77. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 2000; 275:38032-38039 (Pubitemid 32004926)
78. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004; 145:3265-3272 (Pubitemid 38829999)
79. Lin HY, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes phosphorylation of STAT3 and potentiates the action of EGF in cultured cells. Biochem J 1999; 338:427-432 (Pubitemid 129512267)
80. Lin HY, Davis FB, Gordinier JK, Martino LJ, Davis PJ. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol 1999; 276:1014-1024 (Pubitemid 29244654)
81. Shih A, Lin HY, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 2001; 40:2870-2878 (Pubitemid 32198289)
82. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006; 66:7270-7275 (Pubitemid 44197708)
83. Tzirogiannis C, Rho C, Keating T, Hercbergs A, Davis FB, Davis PJ, et al. Enhanced Proliferation of human lung adenocarcinoma and small cell lung carcinoma cells directed from cell surface by thyroid hormone 2007; Abstract # P1-602 at the 89th Annual Meeting of The Endocrine Society.
84. Cody V, Davis PJ, Davis FB. Molecular modeling of the thyroid hormone interactions with αvβ3 integrin. Steroids 2007; 72:165-170 (Pubitemid 46273491)
85. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 2008; 11:269-276
86. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, et al. L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009; [Epub ahead of print].
87. Lu C, Willingham MC, Furuya F, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 2008; 149:3339-3345 (Pubitemid 351919619)
88. Moeller LC, Dumitrescu AM, Refetoff S. Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1α and glycolytic genes. Mol Endocrinol 2005; 19:2955-2963 (Pubitemid 41697714)
89. Lei J, Mariash CN, Bhargava M, Wattenberg EV, Ingbar DH. T3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294:749-754
90. Davis PJ, Davis FB, Mousa SA. Thyroid hormone-induced angiogenesis. 2009 Current Cardiology Reviews 2009; 5:12-16
91. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 2006; 25:407-413 (Pubitemid 46351000)
92. Safer JD, Crawford TM, Holick MF. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology 2004; 145:2357-2361 (Pubitemid 38535065)
93. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 2005; 146:4425-4430 (Pubitemid 41324040)
94. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999; 20:237-242 (Pubitemid 29057555)
95. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives.
96. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003; 23:617-626 (Pubitemid 36358462)
97. Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009; 18:570-574
98. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma Cancer 2005; 103:1122-1128
99. Mishkin SY, Pollack R, Yalovsky MA, Morris HP, Mishkin S. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res 1981; 41:3040-3045 (Pubitemid 11035513)
100. Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol 2007; 4:674. (Pubitemid 350186998)
101. Vetter ML, Kaul S, Iqbal N. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract 2008; 14:618-624
102. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81-83